简介：肺癌患者治疗前的预后评估对制定合理的治疗方案至关重要。^18F-FDGPET／CT作为分子影像检查手段，能有效地反映患者的肿瘤代谢负荷，其中全身肿瘤代谢体积（whole-bodymetabolictumorvolume，MTVwb）及全身病灶总糖酵解值（whole-bodytotallesionglycolysis，TLGwb）作为全身肿瘤代谢负荷参数，在评价预后方面有很好的应用前景。

简介：目的评价双时相显像在胰腺良恶性鉴别诊断中的应用价值。方法对24例胰腺癌患者和10例胰腺良性病变患者进行^18F-FDGPET双时相显像（早注射FDG后50-60min行早期显像,注射后120-150min行延迟显像）,测定两次显像病灶的标准摄取值（standarduptakevalue,SUV）,并计算SUV变化率（ΔSUV）。结果胰腺癌组SUV早期显像=4.63±2.09,SUV延迟显像=5.86±2.74,ΔSUV=（24.76±15.58）%,差异有显著性（t=7.94,P〈0.01）。而胰腺良性病变SUV早期显像=2.48±0.95,SUV延迟显像=2.81±1.18,ΔSUV=（12.66±20.97）%,差异有显著性（t=2.67,P〈0.05）,且胰腺癌组SUV延迟显像明显高于良性病变组（t=2.25,P〈0.05）。结论胰腺恶性病变SUV延迟显像升高的幅度高于良性病变,但黏液腺癌SUV延迟显像升高的幅度低于良性病变,总体而言,双时相显像方法简便,在临床上具有一定的实用价值。

简介：Objective:Toclarifytheprognosticvalueofpost-treatment18F-fluorodeoxyglucose(FDG)positronemissiontomography(PET)/computedtomography(CT)inpatientswithadvancedheadandnecksquamouscellcarcinoma(HNSCC)aftercombinedintra-arterialchemotherapyandradiotherapy(IACR).Methods:Thirty-sixpatientswithHNSCCwhounderwentIACRwererecruited.TheperiodfromtheendofIACRtothelastpost-treatment18F-FDGPET/CTexaminationwas8-12weeks.Bothpatient-basedandlesion-basedanalyseswereusedtoevaluatethePET/CTimages.Forlesion-basedanalysis,36regions(12lesionsofrecurrencesand24scarsatprimarysites)wereselected.TheKaplan-Meiermethodwasusedtoassesstheoverallsurvival(OS)stratifiedby18F-FDGuptakeorvisualinterpretationresults.Results:TwelvepatientswithrecurrencewereidentifiedbysixmonthsafterIACR.Thesensitivityandspecificityinthepatient-basedanalysiswere67%(8/12)and88%(21/24),respectively.ThemeanOSwasestimatedtobe12.1months(95%CI,6.3-18.0months)forthehighermaximumstandardizeduptakevalue(SUVmax)group(n=7)and44.6months(95%CI,39.9-49.3months)forthelowerSUVmaxgroup(n=29).OSinthehigherSUVmaxgroup(cut-offpoint,6.1)orpositivevisualinterpretationgroupwassignificantlyshorterthanthatinthelowerSUVmaxornegativevisualinterpretationgroup(P<0.001andP<0.05,respectively).Conclusions:TheSUVmaxandvisualinterpretationofHNSCConpost-IACR18F-FDGPET/CTcanprovideprognosticsurvivalestimates.

简介：背景与目的：以“C-蛋氨酸（11C-MET）为示踪剂的正电子发射体层成像（PET）可为脑肿瘤的氨基酸代谢提供重要信息，大型氨基酸转运载体1（LATl）和细胞表面抗原4F2重链（4F2hc）所形成的LATl／4F2hc复合物是包括蛋氨酸在内的大型、中性氨基酸的主要转运载体．本研究旨在探讨人脑胶质瘤中11C-MET摄取量与LATl和4F2hc表达的关系。方法：对30例新诊断的脑胶质瘤患者行11C-METPET检查．计算11C-MET最大标准化摄取值（SUVmax）；采用免疫组化方法检测LATl和4F2hc在相同脑胶质瘤标本中的表达；分析11C-METSUVmax、LATl和4F2hc表达水平与胶质瘤临床病理学特征的关系以及三者之间的关系。结果：HC．METSUVmax、LATl和4F2hc表达均随胶质瘤病理级别的升高而明显增强（P=0．000。P=0．028。P=0．003），在高恶性度胶质瘤中11C．METSUVmax、LATl和4F2hc表达也均明显强于低恶性度胶质瘤（P=0．000．P=0．032．P=O．004）：LAT1和4F2hc表达之间存在明显正相关（P=0．036）；uC．METSUVmax与IATl表达也存在明显正相关（P=0．003），但与4F2hc表达无明显相关性（P=0．366）。结论：11C-MET摄取量以及LATl和4F2hc表达与脑胶质瘤的病理学特征关系密切．LATl高表达可能是脑胶质瘤11C-MET摄取量增高的一个重要因素。

简介：Aseventyeightyearsoldmalepatientunderwentawholebody18F-FDGPET/CTimagingtodiagnosethelesionwhichwasshowedintherightlungbyachestXraytestandCTscanbefore.Besidestheintense18F-FDGuptakeofthelesionintherightlung,alesionintheleftparotidglandalsoshowedintense18F-FDGuptake.Toevaluatethepathologyofthelesionintheleftparotidgland,aparotidglandscintigraphyimagingwithTc-99mpertechnetatewasdoneandrevealedaWarthin'stumor.Laterafineneedleaspiration(FNA)confirmedthatitwasaWarthin'stumor.

简介：Objective:Weinvestigatedthecorrelationbetweenthenumberofcirculatingtumorcells(CTCs)andwholebodymetabolictumorvolume(WBMTV)measuredby18F-fluorodeoxyglucose(FDG)positronemissiontomography/computedtomography(PET/CT).TheaimwastoevaluatethevalueoftheincorporationofCTCnumberandWBMTVintheprognosticpredictionofstageIIIsmall-celllungcancer(SCLC).Methods:Onehundredandtwenty-ninepatientswereenrolledinthisstudy.Allpatientsweretreatedwithfourcyclesofaplatinum-basedregimenandconcurrentchestirradiation,followedbyprophylacticcranialirradiation.BloodsamplesforCTCanalysiswereobtainedfrom112patientsbeforetheinitiationofchemotherapy(asabaseline),aftercycle1andaftercycle4.CTCsweremeasuredusingtheCELLSEARCH?system.ThepatientsunderwentpretreatmentFDGPET/CTWBMTV,whichincludedallmalignantlesions.TheSpearmanranktestwasusedtodeterminethecorrelationamongCTCcounts,WBMTVanddiseasestage.Overallsurvival(OS)andprogression-freesurvival(PFS)curveswereproducedusingtheKaplan-Meiermethod,andsurvivaldifferencesbetweengroupswereassessedbythelog-ranktest.Results:ThenumberofCTCsatbaselinedidnotcorrelatewithWBMTVbeforetheinitiationoftherapy(P=0.241).ThenumberofCTCsatbaselineandtheWBMTVbeforetheinitiationoftherapywereindependentrelevantfactorsforPFSandOS.Thesubgroupanalysis(GroupA:CTCcount>19.5andaWBMTV>266.5cm^3;GroupB:CTCcount>19.5andaWBMTV≤266.5cm^3;GroupC:CTCcount≤19.5andaWBMTV>266.5cm^3;GroupD:CTCcount≤19.5andaWBMTV≤266.5cm^3)showedthatthedifferenceswerestatisticallysignificantinthemedianPFS(GroupAvs.D,P<0.001;GroupBvs.D,P=0.018;GroupCvs.D,P=0.029)andinthemedianOS(GroupAvs.D,P<0.001;GroupBvs.D,P=0.012).Conclusions:CTCnumberandWBMTVarerelatedtoprogressionanddeathinpatientswithSCLC.TheincorporationofCTCnumberandWBMTVscanscanprovideadetailedprognosticpredictionforSCLC.